Meta-Analysis of First-Line Triple Therapy for *Helicobacter pylori* Eradication in Korea: Is It Time to Change?

Eun Jeong Gong, * Sung-Cheol Yun, ** Hwoon-Yong Jung, ¹ Hyun Lim, ¹ Kwi-Sook Choi, ¹ Ji Yong Ahn, ¹ Jeong Hoon Lee, ¹ Do Hoon Kim, ¹ Kee Don Choi, ¹ Ho June Song, ¹ Gin Hyung Lee, ¹ and Jin-Ho Kim¹

Received: 27 December 2013
Accepted: 20 March 2014

Address for Correspondence:
Hwoon-Yong Jung, MD
Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul; ¹Department of Gastroenterology, Hallym University Sacred Heart Hospital, Anyang, Korea

*Eun Jeong Gong and Sung-Cheol Yun contributed equally to this work.

INTRODUCTION

*Helicobacter pylori* infection causes chronic gastritis and is associated with an increased risk of upper gastrointestinal diseases, such as peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue lymphoma (1, 2). Although its incidence has declined in developed countries, the prevalence of *H. pylori* remains high in Korea (3-6). The nationwide seroprevalence surveys performed in 1998 and 2005 among asymptomatic Korean adults reported *H. pylori* prevalence rates of 66.9% and 59.5% (5).

Proton pump inhibitor (PPI)-based triple therapy, which consists of PPI, amoxicillin, and clarithromycin, is the recommended first-line treatment for *Helicobacter pylori* infection. However, the eradication rate of triple therapy has declined over the past few decades. We analyzed the eradication rate and adverse events of triple therapy to evaluate current practices in Korea. A comprehensive literature search was performed up to August 2013 of 104 relevant studies comprising 42,124 patients. The overall eradication rate was 74.6% (95% confidence interval [CI], 72.1%-77.2%) by intention-to-treat analysis and 82.0% (95% CI, 80.8%-83.2%) by per-protocol analysis. The eradication rate decreased significantly from 1998 to 2013 (P < 0.001 for both intention-to-treat and per-protocol analyses). Adverse events were reported in 41 studies with 8,018 subjects with an overall incidence rate of 20.4% (95% CI, 19.6%-21.3%). The available data suggest that the effectiveness of standard triple therapy for *H. pylori* eradication has decreased to an unacceptable level. A novel therapeutic strategy is warranted to improve the effectiveness of first-line treatment for *H. pylori* infection in Korea.

Keywords: *Helicobacter pylori*; Eradication; Triple Therapy

Proton pump inhibitor (PPI)-based triple therapy consisting of PPI, amoxicillin, and clarithromycin, is the recommended first-line treatment for *Helicobacter pylori* infection. However, the eradication rate of triple therapy has declined over the past few decades. We analyzed the eradication rate and adverse events of triple therapy to evaluate current practices in Korea. A comprehensive literature search was performed up to August 2013 of 104 relevant studies comprising 42,124 patients. The overall eradication rate was 74.6% (95% confidence interval [CI], 72.1%-77.2%) by intention-to-treat analysis and 82.0% (95% CI, 80.8%-83.2%) by per-protocol analysis. The eradication rate decreased significantly from 1998 to 2013 (P < 0.001 for both intention-to-treat and per-protocol analyses). Adverse events were reported in 41 studies with 8,018 subjects with an overall incidence rate of 20.4% (95% CI, 19.6%-21.3%). The available data suggest that the effectiveness of standard triple therapy for *H. pylori* eradication has decreased to an unacceptable level. A novel therapeutic strategy is warranted to improve the effectiveness of first-line treatment for *H. pylori* infection in Korea.

Proton pump inhibitor (PPI)-based triple therapy, which consists of PPI, amoxicillin, and clarithromycin or metronidazole, is the first-line treatment for *H. pylori* infection (7). Because metronidazole-resistant *H. pylori* strains are reported in 40% or more of clinical isolates, triple therapy with PPI standard dose bis in die (bid, twice a day), amoxicillin 1 g bid, and clarithromycin 500 mg bid is the standard regimen for *H. pylori* eradication in Korea (7-9). However, even with the current treatment regimens, treatment fails in approximately 20% of patients who remain *H. pylori* positive (10, 11). In addition, the prevalence of clarithromycin-resistant *H. pylori* strains is increasing in both Korea and other countries, and the efficacy of PPI-based triple therapies has substantially decreased to 80% or below in most countries in recent decades (11-16). Consequently, whether standard triple therapy should continue as first-line therapy is currently under debate.

Several observational studies assessing trends in *H. pylori* eradication over a number of years have been performed in Korea. In some reports, the eradication rate of standard triple therapy was shown to have decreased to 77.5% in recent years (15, 17). In contrast, other studies reported that the eradication rate remained constant over 5-11 yr, although the eradication rate was found to be below 90% in a per-protocol (PP) analysis (18-20). This discrepancy may be due to geographical differences in antibiotic resistance and to different methods used for determining eradication. We therefore performed a meta-analysis to evaluate the eradication rate and adverse events of first-line triple therapy to verify the effectiveness of current practice in Korea.
MATERIALS AND METHODS

Study selection
A comprehensive literature search was performed to identify relevant studies through August 2013 using computer-assisted bibliographic searches of PubMed, KoreaMed, and KMBASE. Combinations of the following terms were used: *H. pylori* or *H. pylori* and eradication, triple, first-line, proton pump inhibitor, PPI, amoxicillin, clarithromycin, or metronidazole. Abstracts and full papers from relevant studies were reviewed, and those meeting the defined selection criteria were considered for further evaluation. Abstracts presented through August 2013 at the following congresses were also hand-searched: Digestive Disease Week, the United European Gastroenterology Week, the Korean Society of Gastroenterology, the Korean College of Helicobacter and Upper Gastrointestinal Research, and the Korean Association of Internal Medicine. Abstracts of articles in each of these multiple searches were reviewed, and those meeting the inclusion criteria were included. Care was taken to avoid obtaining duplicate data by examining the authors’ names and affiliations for each publication. Overlapping articles and articles unrelated to our analysis were excluded.

Studies were eligible if they had at least one treatment arm and met all of the following criteria: 1) assessed standard triple therapy (a PPI with amoxicillin and clarithromycin) for *H. pylori* eradication; 2) included first-line eradication therapy; 3) demonstrated *H. pylori* infection by at least one high-accuracy diagnostic test (urea breath test, stool antigen test, histological examination, rapid urease test, or culture); 4) confirmed eradication of infection after completion of treatment, based on an appropriate follow-up test; and 5) was the most informative article when multiple articles were published by the same authors or groups.

The quality of each randomized controlled study was assessed by using the Jadad composite scale based on three items: 1) randomization; 2) double blinding; and 3) description of withdrawals and dropouts (21). The selection of studies for this meta-analysis was performed by two independent reviewers. Differences between the two reviewers were resolved by assessment of the full article by a third reviewer. The decision as to whether to include the article was made by consensus.

Data extraction and analysis
Data on the following items were extracted from the selected articles: 1) study design; 2) study period; 3) number of patients enrolled in the study and in each treatment arm; 4) drug regimen, doses, and duration of therapy; 5) diagnostic tests used in the diagnosis of *H. pylori* infection and confirmation of eradication; 6) indications for *H. pylori* eradication; 7) number of patients in whom *H. pylori* infection was successfully eradicated; and 8) number of patients with adverse events and the type of adverse event.

To account for heterogeneity between studies, the overall and yearly eradication rates and their 95% confidence intervals (CIs) were estimated with a random-effect logistic regression model (PROC NLMIXED in SAS software version 9.2, Cary, NC, USA). All reported P values are two-sided, and values of P < 0.05 indicated statistical significance.

RESULTS

We initially screened 282 studies. Of these, 112 reports of first-line standard triple therapy were included in the analysis (Fig. 1). After systematic review of these studies, a total of 104 studies including 38 randomized controlled trials (RCTs) and 66 observational studies were eligible for meta-analysis. The clinical characteristics of the studies are listed in Tables 1 and 2. A total of 42,124 subjects were included, and the sample size per study ranged from 12 to 4,198 subjects.

The overall eradication rate with standard triple therapy was 74.6% (95% CI, 72.1%-77.2%) for intention-to-treat (ITT) analysis and 82.0% (95% CI, 80.8%-83.2%) for PP analysis. The eradication rate showed a decreasing tendency from the years 1998 to 2013 based on ITT and PP analysis (P < 0.001 and P = 0.0003, respectively) (Fig. 2). The eradication rates of the 7-day and 14-day treatments were 81.1% (95% CI, 79.8%-82.3%) and 85.3% (95% CI, 83.5%-87.1%) for PP analysis, respectively.

![Fig. 1. Flowchart of the study design. RCT, randomized controlled trials.](http://jkms.org)
Adverse events were reported in 41 studies (24 RCTs and 17 observational studies) with 8,018 subjects treated with standard triple therapy (22-62). The incidence of adverse events in these studies was 20.4% (95% CI, 19.6%-21.3%). Taste alteration was the most common adverse event, followed by loose stool or diarrhea, abdominal discomfort, and nausea. The percentage of patients who stopped medication due to adverse events was 1.81% (35/1,930), suggesting that most patients could tolerate adverse events.

**DISCUSSION**

In our current study, we performed an up-to-date meta-analysis on the eradication rate of first-line PPI-based triple therapy. The results of our meta-analysis suggest that the efficacy of triple therapy for *H. pylori* infection is lower than desired, with a pooled eradication rate of 74.6% in ITT analysis and 82.0% in PP analysis. In addition, the eradication rate has significantly decreased over the last 16 yr.

Since 1998, PPI-based triple therapy has been recommended as the first-line therapy for *H. pylori* eradication in Korea. However, eradication rates have been declining, and, as of 2000, decreased to below 80% (11, 48), thereby failing to meet the requirements of the Asia-Pacific Consensus Guidelines, which state that a success rate of > 80% in ITT analysis and > 90% in PP analysis is needed for a regimen to be considered suitable.
Table 2. Characteristics of the observational studies included in the meta-analysis

| Study (yr) (reference No.) | Format | No. of patients | Indication | Duration of therapy (days) | Methods for confirming eradication |
|----------------------------|--------|----------------|------------|---------------------------|---------------------------------|
| Kim et al. (2013) (89)     | Full paper | 110             | PUD/EGC/NUD | NR                        | H/R/PU                          |
| Yoon et al. (2012) (18)    | Full paper | 3,969           | PUD/NUD     | 14                        | C/H/R/U                         |
| Kang et al. (2012) (90)    | Full paper | 153             | EGC/dysplasia | 7                         | H/R/PU                          |
| Lee et al. (2012) (91)     | Abstract | 1,547           | NR          | 7/14                      | NR/NR                           |
| Kim et al. (2012) (92)     | Abstract | 1,466           | NR          | 7/14                      | NR/NR                           |
| Moon et al. (2012) (93)    | Abstract | 43              | PUD/EGC/MALT | 7                         | U                               |
| Chung et al. (2011) (15)   | Full paper | 4,198           | PUD/AG/EGC/NUD | 7                         | U                               |
| Seo et al. (2011) (31)     | Full paper | 204             | PUD/AG      | 7                         | U                               |
| Kim et al. (2011) (32)     | Full paper | 186             | PUD/AG      | 7                         | U                               |
| Kim et al. (2011) (94)     | Full paper | 120             | PUD/AG      | 7                         | C/H/R/U                         |
| Moon et al. (2011) (95)    | Abstract | 102             | NR          | 7                         | U                               |
| Moon et al. (2011) (96)    | Abstract | 85              | NR          | 7                         | U                               |
| Moon et al. (2011) (97)    | Abstract | 770             | NR          | 7                         | U                               |
| Choi et al. (2011) (34)    | Abstract | 38              | NR          | 7                         | U                               |
| Kwon et al. (2010) (36)    | Full paper | 135             | PUD/AG      | 7                         | U                               |
| Hong et al. (2010) (66)    | Full paper | 129             | PUD/AG/dysplasia/EGC | 7                         | U                               |
| Cho et al. (2010) (19)     | Full paper | 709             | PUD/AG/gastric poly/EGC/MALT | 7                         | U                               |
| Pak et al. (2010) (97)     | Full paper | 986             | PUD/AG      | 7/14                      | U                               |
| Lee et al. (2010) (98)     | Full paper | 798             | NR          | 7                         | H/U                             |
| Ahn et al. (2010) (99)     | Full paper | 145             | NR          | 7                         | H/R/PU                          |
| Oh et al. (2009) (100)     | Full paper | 210             | PUD/AG      | 7                         | U                               |
| Jung et al. (2009) (101)   | Full paper | 163             | PUD/AG      | 7/14                      | H/R/PU                          |
| Chung et al. (2009) (17)   | Full paper | 1,716           | PUD/gastric erosion | 7                         | U                               |
| Song et al. (2009) (102)   | Full paper | 1,789           | PUD/NUD/EGC/MALT | 7/14                     | H/R/PU                          |
| Cho et al. (2009) (103)    | Full paper | 615             | PUD/EGC/MALT | 7                         | H/R/PU                          |
| Huh et al. (2009) (104)    | Abstract | 859             | PUD/AG      | 7                         | U                               |
| Kang et al. (2008) (105)   | Full paper | 327             | PUD/AG/EGC/dysplasia | 7                         | U                               |
| Hong et al. (2008) (43)    | Full paper | 2,145           | PUD/NUD     | 7                         | H/R/PU                          |
| Nam et al. (2008) (106)    | Full paper | 597             | PUD          | 7                         | H/R/PU                          |
| Chung et al. (2008) (107)  | Full paper | 50              | PUD/EGC     | 7                         | U                               |
| Jo et al. (2008) (108)     | Full paper | 39              | PUD          | 7                         | U                               |
| Nam et al. (2008) (109)    | Abstract | 341             | PUD          | 7                         | NR                              |
| Kim et al. (2008) (110)    | Abstract | 166             | PUD/NUD/EGC | 7/14                      | U                               |
| Na et al. (2007) (20)      | Full paper | 3,267           | PUD          | 7                         | H/R/PU                          |
| Paik et al. (2007) (46)    | Full paper | 280             | PUD/AG      | 7                         | R/U                             |
| Kang et al. (2007) (111)   | Full paper | 36              | PUD          | 7                         | H/R/PU                          |
| Nam et al. (2007) (112)    | Abstract | 363             | PUD          | 7                         | U                               |
| Lee et al. (2007) (113)    | Abstract | 200             | NR          | 7                         | U                               |
| Lee et al. (2007) (47)     | Abstract | 220             | PUD          | 7/14                      | NR                              |
| Kang et al. (2008) (49)    | Full paper | 61              | PUD/AG/EGC  | 7                         | H/R/PU                          |
| Choi et al. (2006) (12)    | Full paper | 525             | PUD          | 7                         | H/R/PU                          |
| Byun et al. (2006) (114)   | Full paper | 195             | PUD/AG/gastric poly/dysplasia/MALT/FHx | 7                         | H/U                             |
| Suh et al. (2006) (115)    | Full paper | 297             | PUD/NUD     | 7                         | U                               |
| Lee et al. (2006) (116)    | Full paper | 236             | NR          | 7                         | U                               |
| Kim et al. (2006) (117)    | Full paper | 426             | PUD          | 7                         | U                               |
| Kweon et al. (2005) (52)   | Full paper | 352             | PUD/gastric erosion | 7/14 | H/R/PU |
| Koo et al. (2005) (118)    | Abstract | 375             | PUD          | 7/14                      | U                               |
| Choi et al. (2003) (53)    | Full paper | 88              | PUD          | 7                         | U                               |
| Jung et al. (2003) (119)   | Full paper | 46              | PUD          | 7                         | H/R/PU                          |
| Kim et al. (2003) (120)    | Abstract | 426             | PUD          | 7                         | U                               |
| Chung et al. (2003) (121)  | Abstract | 525             | PUD          | 7/14                      | H/R/PU                          |
| Lee et al. (2002) (122)    | Full paper | 28              | PUD          | 7/14                      | U                               |
| Choi et al. (2002) (123)   | Full paper | 106             | PUD          | 7                         | H                               |
| Lee et al. (2002) (124)    | Full paper | 173             | PUD/AG      | 7                         | H/R/PU                          |
| Hoo et al. (2002) (125)    | Full paper | 96              | PUD/AG      | 10                        | H/R/PU                          |
| Kim et al. (2002) (126)    | Abstract | 1,150           | NR          | 7/14                      | U                               |
| Choi et al. (2002) (127)   | Abstract | 269             | PUD          | 7/14                      | H/R/PU                          |
| Kim et al. (2002) (128)    | Full paper | 39              | PUD          | 7/14                      | H/R/PU                          |
| Jung et al. (2000) (55)    | Full paper | 73              | PUD          | 7                         | C/H/R/PU                        |
| Song et al. (2000) (56)    | Full paper | 42              | PUD/AG      | 7                         | H/R/PU                          |
| Park et al. (2000) (129)   | Full paper | 460             | PUD/NUD     | 7                         | H/R/PU                          |
| Kim et al. (1999) (59)     | Full paper | 64              | PUD          | 14                        | H/R/PU                          |
| Choi et al. (1999) (60)    | Full paper | 42              | PUD          | 7                         | H/R/PU                          |
| Oh et al. (1999) (130)     | Full paper | 132             | PUD/AG/MALT | 7                         | H                               |
| Kim et al. (1998) (61)     | Full paper | 38              | PUD/AG      | 14                        | H                               |
| Park et al. (1998) (62)    | Abstract | 29              | PUD          | 7/10/14                   | NR                              |

AG, atrophic gastritis; C, culture; EGC, early gastric cancer; FHx, family history of gastric cancer; H, histology; MALT, mucosa-associated lymphoid tumor; NR, not reported; NUD, non-ulcer dyspepsia; PPI, proton pump inhibitor; PUD, peptic ulcer disease; R, rapid urease test; S, serology; U, urea breath test.
for first-line eradication therapy (19, 42, 63).

There are several known factors that affect the eradication of H. pylori, such as antibiotic resistance, geographical area, patient age, smoking status, compliance, duration of therapy, bacterial density, Cag A, gastric acid concentration, individual response to PPI, and the presence of CYP2C19 polymorphism (10, 37, 64, 65). Among these factors, the main cause of the low eradication rate is presumed to be clarithromycin resistance. In Korea, the rate of resistance to clarithromycin was 5.9% before 2000, but has rapidly increased to 38.5% in the period of 2007 to 2009 (9, 16, 66-68). These rates are much higher than in other countries, such as Italy, and the main reason for this discrepancy may be the wide national and regional variations in the prevalence of antibiotic resistance (69). Clarithromycin resistance has been associated with cross-resistance caused by previous treatment with macrolides (70). In clinical practice, such antibiotics are usually prescribed for respiratory infections and are widely used for H. pylori eradication treatment. In addition, antibiotic treatment interruption due to gastrointestinal adverse events, such as diarrhea, nausea, vomiting, and abdominal discomfort, may be another reason for increased antibiotic resistance. Whereas an eradication rate higher than 75% is still achieved despite metronidazole resistance, clarithromycin resistance lowers the eradication rate by 20%, making it difficult to achieve an 80% eradication rate (71, 72). Potential approaches to overcome this resistance problem include patient-tailored, sequential, or concomitant therapies.

Increasing the duration of treatment may prove effective in curing infection, but this hypothesis remains to be validated. The majority of recently recommended eradication therapy regimens are 7-days in duration, which conveys advantages with respect to compliance and medical cost, while maintaining a similar eradication rate to that of longer regimens (73). The Asia-Pacific Consensus Guidelines and Japanese Consensus reports recommend a 7-day PPI-based triple therapy, whilst the Korean College of Helicobacter and Upper Gastrointestinal Research recommend 7-day or 14-day PPI-based triple therapy (74, 75). In Korea, 7-day PPI-based triple therapy has a PP eradication rate of 90%, which is not inferior to that of the 10-day or 14-day therapy (55, 60). However, in a recent study, although the 7-day PPI-based triple therapy was not inferior to the 14-day therapy, neither of the treatment durations provided an acceptable eradication rate of 90% in the PP analysis (11, 38). These studies, which were performed in Korea, were unable to provide conclusive evidence that a prolonged treatment for 2 weeks could counteract resistance to clarithromycin. Moreover, if the cause of treatment failure is antibiotic resistance, extension of the treatment period would not be expected to increase the eradication rate. Therefore, other strategies that achieve higher H. pylori eradication rates are needed, in addition to prolonged treatment duration, to increase the eradication rate in Korea.

Our present study is the largest study to date examining H. pylori eradication in Korea; however, there are several limitations. First, although we tried to include data from all over Korea, our data may not be representative of the entire Korean population. Second, we could not assess the antibiotic resistance rates and precise compliance rates in each study population. Therefore, there may be other factors not included in our analysis that influence the eradication rate of H. pylori.

In conclusion, conflicting results have been reported worldwide with regard to H. pylori eradication with standard triple therapy. Our data support the evidence for a decreased eradication rate of H. pylori, suggesting that a novel therapeutic strategy is warranted to improve first-line treatment for H. pylori infection in Korea.

DISCLOSURE

The authors have no competing conflicts of interest to disclose.

ORCID

Eun Jeong Gong http://orcid.org/0000-0003-3996-3472
Sung-Cheol Yun http://orcid.org/0000-0001-8503-109X
Hwoon-Yong Jung http://orcid.org/0000-0003-1281-5859
Hyun Lim http://orcid.org/0000-0001-6581-6420
Kwi-Sook Choi http://orcid.org/0000-0002-1190-7092
Ji Yong Ahn http://orcid.org/0000-0002-0030-3744
Jeong Hoon Lee http://orcid.org/0000-0002-0778-7585
Do Hoon Kim http://orcid.org/0000-0002-4250-4683
Kee Don Choi http://orcid.org/0000-0002-2517-4109
Ho June Song http://orcid.org/0000-0001-9255-1464
Gin Hyug Lee http://orcid.org/0000-0003-3776-3928
Jin-Ho Kim http://orcid.org/0000-0002-6533-3127
REFERENCES

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-86.

2. McColl KE. Clinical practice: helicobacter pylori infection. N Engl J Med 2010; 362: 1597-604.

3. Jung JH, Choi KD, Han S, Jung HY, Do MY, Chang HS, Choe JW, Lee GH, Song HJ, Kim DH, et al. Seroconversion rates of Helicobacter pylori infection in Korean adults. Helicobacter 2013; 18: 299-308.

4. Lim SH, Kwon JW, Kim N, Kim GH, Kang JM, Park MJ, Yim JY, Kim HU, Baik GH, Seo GS, et al. Prevalence and risk factors of Helicobacter pylori infection in Korea: nationwide multicenter study over 13 years. BMC Gastroenterol 2013; 13: 104.

5. Yim JY, Kim N, Choi SH, Kim YS, Cho KR, Kim SS, Seo GS, Kim HU, Baik GH, Sin CS, et al. Seroprevalence of Helicobacter pylori in South Korea. Korean J Gastroenterol 2007; 12: 333-40.

6. Kim JH, Kim HY, Kim NY, Kim SW, Kim JG, Kim JJ, Roe IH, Seo JK, Sim JG, Ahn H, et al. Seroepidemiological study of Helicobacter pylori infection in asymptomatic people in South Korea. J Gastroenterol Hepatol 2001; 16: 969-75.

7. Kim N, Kim JJ, Choe YH, Kim HS, Kim JJ, Chung IS; Korean College of Helicobacter and Upper Gastrointestinal Research; Korean Association of Gastroenterology. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol 2009; 54: 269-78.

8. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 2004; 48: 4843-7.

9. Kim JH, Reddy R, Lee M, Kim JG, El-Zaatari FA, Osato MS, Graham DY, Kwon DH. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother 2001; 47: 459-61.

10. Calvet X, García N, López T, Gisbert JP, Gené E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 603-9.

11. Kim BG, Lee DH, Ye BD, Lee KH, Kim BW, Kim SG, Kim SW, Kim SK, Kim JH, Kim HY, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007; 12: 31-5.

12. Choi YS, Cheon JH, Lee JJ, Kim SG, Kim JS, Kim N, Lee DH, Kim JM, Jung HC, Song IS. The trend of eradication rates of first-line triple therapy for Helicobacter pylori infection: single center experience for recent eight years. Korean J Gastroenterol 2006; 48: 156-61.

13. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 321-31.

14. Kim JY, Kim N, Kim SJ, Baik GH, Kim GH, Kim JM, Nam RH, Kim HB, Lee DH, jung HC, et al. Regional difference of antibiotic resistance of Helicobacter pylori strains in Korea. Korean J Gastroenterol 2011; 57: 221-9.

15. Chung JW, Lee GH, Han JH, Jeong JH, Choi KS, Kim DH, Jung KW, Choi KD, Song HJ, Jung HY, et al. The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea. Hepatogastroenterology 2011; 58: 246-50.

16. Kim JM, Kim JS, Jung HC, Kim N, Song IS. Antibiotic resistance of Helicobacter pylori isolated from Korean patients in 2003. Korean J Gastroenterol 2004; 44: 126-35.

17. Chung WC, Lee KM, Paik CN, Lee JR, Jung SH, Kim JD, Han SW, Chung JS. Inter-departmental differences in the eradication therapy for Helicobacter pylori infection: a single center study. Korean J Gastroenterol 2009; 53: 221-7.

18. Yoon JH, Baik GH, Sohn KM, Kim DY, Kim YS, Suk KT, Kim JB, Kim DJ, Kim JB, Shin WG, et al. Trends in the eradication rates of Helicobacter pylori infection for eleven years. World J Gastroenterol 2012; 18: 6628-34.

19. Cho DK, Park SY, Kee WJ, Lee JH, Ki HS, Yoon KW, Cho SB, Lee WS, Joo YE, Kim HS, et al. The trend of eradication rate of Helicobacter pylori infection and clinical factors that affect the eradication of first-line therapy. Korean J Gastroenterol 2010; 55: 368-75.

20. Na HS, Hong SJ, Yoon HJ, Maeng JH, Ko BM, Jung IS, Ryu CB, Kim JO, Cho YJ, Lee JS, et al. Eradication rate of first-line and second-line therapy for Helicobacter pylori infection, and reinfection rate after successful eradication. Korean J Gastroenterol 2007; 50: 170-5.

21. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.

22. Lee HJ, Kim JJ, Cheung DY, Kim TH, Jun EJ, Oh JH, Chung WC, Kim BW, Kim SS, Park SH, et al. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J Infect Dis 2013; 208: 1123-30.

23. Kim SY, Lee SW, Hyun JJ, Jung SW, Koo JS, Yim HJ, Park JJ, Chun HJ, Choi JH. Comparative study of Helicobacter pylori eradication rates with 5-day quadruple “concomitant” therapy and 7-day standard triple therapy. J Clin Gastroenterol 2013; 47: 21-4.

24. Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, Seo HE, Lee JH, Yang CH, Kim ES, Cho KB, et al. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naive patients. Aliment Pharmacol Ther 2012; 35: 56-65.

25. Oh HS, Lee DH, Seo YJ, Cho YR, Kim N, Jeoung SH, Kim JW, Hwang JH, Park YS, Lee SH, et al. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. J Gastroenterol Hepatol 2012; 27: 504-9.

26. Kim SY, Jung SW, Kim JH, Koo JS, Yim HJ, Park JJ, Chun HJ, Lee SW, Choi JH. Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea. Br J Clin Pharmacol 2012; 73: 140-3.

27. Chung JW, Jung YK, Kim YJ, Kwon KA, Kim JH, Lee JJ, Lee SM, Hahm KB, Lee SM, Jeong JY, et al. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial. J Gastroenterol Hepatol 2012; 27: 1675-80.

28. Choi HS, Chun HJ, Park SH, Keun B, Seo YS, Kim YS, Jeen YT, Um SH, Lee HS, Kim CD, et al. Comparison of sequential and 7-, 10-, 14-day triple therapy for Helicobacter pylori infection. World J Gastroenterol 2012; 18: 2377-82.

29. Kim YS, Kim SJ, Yoon JH, Suk KT, Kim JB, Kim DJ, Kim DY, Min HJ, Park SH, Shin WG, et al. Randomised clinical trial: the efficacy of a 10-
day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011; 34: 1098-105.

30. Choi KH, Chung WC, Lee KM, Paik CN, Kim EI, Kang BK, Oak JH, Jung SH. Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastrointestinal disease: a double-blind, randomized controlled trial. J Korean Med Sci 2011; 26: 785-90.

31. Seo JY, Kim MJ, Ko KH, Kim DH, Lim DS, Chon HR. Efficacy of esacbet sodium for Helicobacter pylori eradication, combined with lansoprazole-based triple regimen: a prospective study. Korean J Med 2011; 80: 546-52.

32. Kim JY, Lee DH, Son JH, Kim JY, Kwon JE, Park YS, Kim N, Shin CM, Jung HC, Song IS. Effect of additional esacbet sodium on conventional triple therapy for Helicobacter pylori eradication in Korea. Korean J Gastroent Endosc 2011; 42: 349-55.

33. Moon B, Lim H, Lee S, Han K, Jung J, Lee Y. Efficacy of concomitant nonbismuth-based quadruple therapy as first-line treatment for eradication of Helicobacter pylori [Abstract]. Helicobacter 2011; 16: 131.

34. Choi C, Lee D, Chon I, Park H, Kim N, Jeong S, Kim J, Hwang J. Concomitant therapy was more effective than PPI-based triple therapy in Korea: a preliminary report [Abstract]. Helicobacter 2011; 16: 136.

35. Song MJ, Park DI, Park JH, Kim HI, Cho YK, Sohn CI, Jeon WK, Kim BI. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter 2010; 15: 206-13.

36. Kwon JH, Lee DH, Song BJ, Lee JW, Kim N, Shin CM, Jung HC, Song IS. Effect of additional esacbet sodium on conventional triple therapy in eradication of Helicobacter pylori infection in Korea: a retrospective study. Helicobacter 2010; 15: 148-53.

37. Kim SY, Lee SW, Jung SW, Koo JS, Yim HJ, Park JH, Chun HJ, Lee HS, Choi JH, Kim CD, et al. Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study. Helicobacter 2008; 13: 282-7.

38. Kim N, Park SH, Seo GS, Lee SW, Kim JW, Lee KJ, Shin WC, Kim TN, Park MI, Park JH, et al. Lefutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea. Helicobacter 2008; 13: 542-9.

39. Kim MN, Kim N, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Kim JS, Jung HC, et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 2008; 13: 261-8.

40. Kim HW, Kim GH, Cheong JY, Yang US, Park SK, Song CS, Kang DH, Song GA. Helicobacter pylori eradication: a randomized prospective study of triple therapy with or without esacbet sodium. World J Gastroenterol 2008; 14: 908-12.

41. Jung JM, Shim KN, Oh HJ, Na YJ, Jung HS, Jung SA, Yoo K. Role of antisecretory treatment in addition to Helicobacter pylori eradication triple therapy in the treatment of peptic ulcer. Korean J Gastroenterol 2008; 51: 11-8.

42. Choi WH, Park DI, Oh SJ, Baek YH, Hong CH, Hong EJ, Song MJ, Park SK, Park JH, Kim HJ, et al. Effectiveness of 10 day sequential therapy for Helicobacter pylori eradication in Korea. Korean J Gastroenterol 2008; 51: 280-4.

43. Hong EJ, Park DI, Oh SJ, Song MJ, Choi WH, Hong CH, Park JH, Kim HJ, Cho YK, Shon CI, et al. Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors. Korean J Gastroenterol 2008; 52: 80-5.

44. Park SK, Park DI, Choi JS, Kang MS, Park JH, Kim HI, Cho YK, Sohn CI, Jeon WK, Kim BI. The effect of probiotics on Helicobacter pylori eradication. Hepatogastroenterology 2007; 54: 2632-6.

45. Choi HS, Park DI, Hwang SJ, Park JS, Kim HI, Cho YK, Sohn CI, Jeon WK, Kim BI. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate. Helicobacter 2007; 12: 638-42.

46. Paik WH, Kim YJ, Kim IK, Lee JK, Lee CH, Chung GE, Hong KS, Park YS, Hwang JH, Kim JW, et al. Comparison of the eradication rates of one-week low-dose triple therapy with standard-dose triple therapy for Helicobacter pylori infection. Korean J Gastrointest Endosc 2007; 35: 1-5.

47. Lee K, Kim T, Jang B, Lee H, Eun J, Kim K, Lee S, Choi J, Park Y, Moon H, et al. Comparison of the first-line triple therapy for Helicobacter pylori eradication according to the duration of the treatment and trends of eradication rate [Abstract]. Korean J Gastroenterol 2007; 1: 304.

48. Lee JH, Hong SP, Kwon CJ, Phyun LH, Lee BS, Song HU, Ko KH, Hwang SG, Park PW, Rim KS, et al. The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2006; 48: 19-24.

49. Kang MS, Park DI, Yun JW, Oh SY, Yoo TW, Park JH, Kim HI, Cho YK, Sohn CI, Jeon WK, et al. Levofloxacin-azithromycin combined triple therapy for Helicobacter pylori eradication. Dig Dis Sci 2005; 50: 626-9.

50. Jung HI, Choi MH, Kim YS, Seo YA, Baik KH, Baik IH, Eun CS, Kim JB, Kae SH, Kim DJ, et al. Effectiveness of triple therapy and quadruple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2005; 46: 368-72.

51. Keum B, Lee SW, Kim SY, Chung BS, Yim HJ, Jeen YH, Lee HS, Chun HJ, Um SH, et al. Comparison of Helicobacter pylori eradication rate according to different PPI-based triple therapy: omeprazole, rabeprazole, esomeprazole and lansoprazole. Korean J Gastroenterol 2005; 46: 433-9.

52. Choi BI, Yang SY, Park ET, Jang YS, Lee YI, Lee SH, Seol SY, Chung JM. A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer. Korean J Gastroenterol 2003; 42: 102-7.

53. Cho YJ, Chun HJ, Kim ST, Koh DW, Park JH, Park DK, Park CH, Lee SJ, Jeen YT, Lee HS, et al. Analysis of eradication rate of Helicobacter pylori according to treatment duration by using 13C-urea breath test comparison of OAC 7, 10 or 14 days regimen. Korean J Gastrointest Endosc 2001; 23: 207-12.

54. Jung IS, Hong SJ, Kim JO, Cho JY, Lee MS, Shim CS. The effect of Helicobacter pylori eradication of triple therapy with omeprazole, amoxicillin and clarithromycin. Korean J Med 2006; 58: 626-31.

55. Song HJ, Yang YS, Lee IS, Lee KM, Lee DS, Kim SW, Kim SS, Han SW, Choi KY, Chung IS, et al. Efficacy and tolerability of pantoprazole-based triple therapy in eradication of Helicobacter pylori in patients with peptic ulcer and/or gastritis. Korean J Gastroenterol 2000; 36: 185-91.
Gong EJ, et al. • Helicobacter pylori Eradication in Korea

57. Ryu KH, Kim YH, Lee KT, Lee JK, Lee JH, Rhee PL, Kim JJ, Koh KC, Paik SW, Rhee JC, et al. Comparison of the efficacy of triple therapy with omeprazole, amoxicillin and clarithromycin in Helicobacter pylori eradication according to the duration in patients with peptic ulcer disease [Abstract]. Korean J Med 1999; 57: 86.

58. Kim JH, Lee KT, Lee SM, Kim SH, Lee BS, Kim NJ, Jeong HY, Lee HY, Kim SY, Kim YK. Efficacy of ten days of clarithromycin, amoxicillin and omeprazole in eradicating Helicobacter pylori infection. Korean J Med 1999; 56: 581-9.

59. Kim JI, Chung IS, Bhang CS, Park SH, Choi MG, Kim JK, Han SW, Sun HS, Park DH, Chang ED. Factors influencing eradication of Helicobacter pylori in patients with peptic ulcer disease. J Korean Gastroenterol 1999; 33: 624-34.

60. Choi II, Lee WJ, Kim YS, Kim JS, Jung HC, Song IS, Kim CY. Efficacy of 1-week pantoprazole-based triple therapy in eradicating Helicobacter pylori without additional acid suppression therapy. Korean J Gastroenterol 1999; 34: 724-32.

61. Kim BS, Chung IS, Park DH, Yang YS, Lee DS, Kim SW, Byun BH, Choi JY. The therapeutic effect of triple therapy in Helicobacter pylori infection. Korean J Gastroenterol 1998; 38: 32-7.

62. Park Y, Yi JS, Kwon KS, Cho HK, Choi W, Lee DH, Kim PS, Kim H, Shin YW, Kim YS. Efficacy of triple therapy with omeprazole, amoxicillin and clarithromycin in Helicobacter pylori eradication according to the treatment duration. Korean J Med 1998; 55: 219.

63. Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81.

64. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008; 148: 925-31.

65. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, Alpert LC, Genta RM. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-6.

66. Hwang TJ, Kim N, Kim HB, Lee BH, Nam RH, Park JH, Lee MK, Park YS, Lee DH, Jung HC, et al. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol 2010; 44: 536-43.

67. Bang SY, Han DS, Eun CS, Kim JE, Ahn SB, Sohn JH, Jeon YC, Kang JO. Changing patterns of antibiotic resistance of Helicobacter pylori in patients with peptic ulcer disease. Korean J Gastroenterol 2007; 50: 356-62.

68. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-53.

69. Kim N, Kim JM, Kim CH, Park YS, Lee DH, Kim JS, Jung HC, Song IS. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol 2006; 40: 683-7.

70. Xia HX, Buckley M, Keane CT, O’Morain CA. Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. J Antimicrob Chemother 1996; 37: 473-81.

71. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spérandio J. Bismuth-based quadruple therapy using a single capsule of bismuth subcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Ann J Gastroenterol 2003; 98: 562-7.

72. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE Study. Gastroenterology 2002; 123: 1763-9.

73. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147: 553-62.

74. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-600.

75. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Otta H, Uemura N, Murakami K, Satoh K, Sugano K, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1-20.

76. Rew JS, Park SY, Ki HS, Jun CH, Park CH, Kim HS, Choi SK. An antimicrobial susceptibility-guided versus standard triple therapy for Helicobacter pylori eradication in patients with gastric epithelial neoplasia [Abstract]. Gastroenterology 2013; 144: S331.

77. Kim N, Nam RH, Kim JY, Lee MK, Lee JW. Comparison of ten-day, fifteen-day sequential therapy and proton-pump inhibitor-based triple therapy in Korea: a prospective randomized study [Abstract]. Gastroenterology 2012; 142: S484.

78. Lee JH, Jung HY, Choi KD, Song HJ, Lee GH, Kim JH. The influence of CYP2C19 polymorphism on eradication of Helicobacter pylori: a prospective randomized study of lansoprazole and rabeprazole. Gut Liver 2010; 4: 201-6.

79. Park S, Chun H, Kim E, Park S, Jung E, Lee S, Jung J, Kwon Y, Keum B, Seo Y, et al. The 10-day sequential therapy for Helicobacter pylori eradication in Korea: less effective than expected [Abstract]. Gastroenterology 2009; 136: A339-40.

80. Lee D, Lee S, Chun H, Jung H, Kim J. Two weeks triple regimen with PPI, clarithromycin and amoxicillin is more effective in H. pylori eradication than one week triple regimen in patients with peptic ulcer disease in South Korea [Abstract]. Helicobacter 2004; 9: 570.

81. Baik GH, Kim DJ, Kim JB, Seo YA, Kae SH, Jang HJ, Kim KH, Park CH, Kim HY. Efficacy of rabeprazole-based 7-day and 14-day triple therapy in patients with Helicobacter pylori-related peptic ulcer [Abstract]. Helicobacter 2002; 7: 331-6.

82. Baik GH, Kim DJ, Kim JB, Seo YA, Kae SH, Jang HJ, Kim KH, Park CH, Kim HY. Efficacy of rabeprazole-based 7-day and 14-day triple therapy in patients with Helicobacter pylori-related peptic ulcer [Abstract]. Korean J Gastroenterol 2004; 1: 285.

83. Lee DJ, Lee JE, Choe JW, Kim GH, O HJ, O HA, Lee HC, Kim JH, Kim TN, Jeong MG. Comparison of one-week and two-week triple therapy in Helicobacter pylori eradication [Abstract]. Korean J Gastroenterol 2003; 1: 546.

84. Kim JI, Park SH, Kim JK, Chung IS, Chung KW, Sun HS. The effects of nocturnal acid breakthrough on Helicobacter pylori eradication. Helicobacter 2002; 7: 331-6.

85. Choi II, Jung HC, Choi KW, Kim JH, Ahn DS, Yang US, Rew JS, Lee SI, Rhee JC, Chung IS, et al. Efficacy of low-dose clarithromycin triple therapy and tindazole-containing triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16: 145-51.

86. Lee SW, Kim KH, Oh HJ, Kim TD, Lee EJ, Jang BI, Kim TN, Chung MN. Ulcer healing effect of Helicobacter pylori eradication in patients with Helicobacter pylori-associated peptic ulcer. Korean J Med 2002; 63: 134-
Helicobacter pylori. Korean J Gastroenterol 2006; 48: 172-9.
115. Suh SO, Lee DH, Park YS, Hwang JH, Kim JW, Kim N, Jung H, Song IS. Difference in Helicobacter pylori eradication rates in patients with peptic ulcer and non-ulcer dyspepsia. Korean J Med 2006; 70: 505-10.
116. Lee CH, Lee JK, Kim JW, Park YS. The effectiveness of bismuth and eupatilin along with proton-pump inhibitor-based triple regimen in eradication of Helicobacter pylori [Abstract]. Helicobacter 2006; 11: 392.
117. Kim D. Efficacy of esomeprazole and rabeprazole for Helicobacter pylori eradication in patients with peptic ulcer [Abstract]. Helicobacter 2006; 11: 394.
118. Koo JS, Lee SW, Jung WW, Han WS, Lee JS, Kim MJ, Lee HS, Choi JH, Kim CD, Ryum HS, et al. Helicobacter pylori eradication rate in patients with scar stage of peptic ulcer [Abstract]. Korean J Med 2005; 69: 193.
119. Jung HK, Jin KI, You MA, Bae KS, Kwon JM, Lee JS, Kim DY, Moon IH. Eradication rate of lansoprazole-based triple therapy in peptic ulcer patients with Helicobacter pylori and efficacy of urea breath test in evaluating Helicobacter pylori eradication. Infect Chemother 2003; 35: 154-9.
120. Kim J, Kim J, Lee D, Lee Y, Rhee P, Rhee C. Efficacy of esomeprazole and rabeprazole for Helicobacter pylori eradication in patients with peptic ulcer [Abstract]. Helicobacter 2003; 8: 469.
121. Choug R, Lee S, Kim M, Jang Y, Kim J, Lee H. The eradication rate of Helicobacter pylori in complicated peptic ulcer patients [Abstract]. Helicobacter 2003; 8: 472.
122. Lee JH, Rhee PL, Hyun JG, Choe WH, Lim YJ, Ahn BH, Lee YW, Kim YH, Kim JJ, Koh KC, et al. Eradication of Helicobacter pylori in patients with S-2 stage duodenal ulcer scar an interim report. Korean J Gastrointest Endosc 2002; 24: 71-5.
123. Choi HS, Kim JH, Kim MC, Jeong TH. Eradication rate of one-week triple therapy for peptic ulcer with Helicobacter pylori and clinical characteristics of patients with failed eradication. J Korean Acad Fam Med 2002; 23: 60-7.
124. Lee JH, Kim HY, Park JK, Shim JH, Kim JW, Hwang JH, Kim BG, Chang DK, Kim JW, Kim NY, et al. Current effectiveness of Helicobacter pylori eradication treatment in primary care setting in Korea. Korean J Med 2003; 65: 422-5.
125. Heo JH, Nam SW, Roe IH, Yang MB, Kim JT, Song IH, Lim CY, Kim JW, Shin JH. Correspondence between H. pylori eradication failure rate and clarithromycin resistance rate [Abstract]. Korean J Gastroenterol 2002.
126. Kim KO, Chun HJ, Jeong RS, Kim YS, Kim YS, Park CH, Jeen YT, Lee HS, Lee SW, Um S, et al. Comparison of 7-day and 14-day triple therapy in Helicobacter pylori eradication in elderly subjects [Abstract]. Korean J Med 2002; 63: 83.
127. Choi KD, Kim JS, Jung HC, Song IS. Efficacy of rabeprazole-based triple therapy regimen for the eradication of Helicobacter pylori in patients with peptic ulcer disease [Abstract]. Korean J Helicobacter Up Gastrointest Res 2003.
128. Kim YJ, Lee SY, Choi SH, Kim YJ. Treatment behavior for the eradication of Helicobacter pylori in peptic ulcer. Korean J Aerosp Environ Med 2002; 12: 28-31.
129. Park JS, Hong SS, Lee YS, Lee E, Myung SJ, Jung HY, Yang SK. Eradication rate for Helicobacter pylori in the elderly. J Korean Geriatr Soc 2000; 4: 138-47.
130. Oh MK, Choi WS, Lee YB, Chung HR, Kang GH, Kim JS. The effect of smoking on eradication of Helicobacter pylori. J Korean Acad Fam Med 1999; 20: 991-9.